Business Description
ARCA biopharma Inc
NAICS : 325413
SIC : 2835
ISIN : US00211Y4070
Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 163.15 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 37.5 | |||||
| 3-Year EPS without NRI Growth Rate | 43.7 | |||||
| 3-Year FCF Growth Rate | 40.4 | |||||
| 3-Year Book Growth Rate | -19.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.51 | |||||
| 9-Day RSI | 29 | |||||
| 14-Day RSI | 34.32 | |||||
| 6-1 Month Momentum % | 81.82 | |||||
| 12-1 Month Momentum % | 45.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 26.61 | |||||
| Quick Ratio | 26.61 | |||||
| Cash Ratio | 26.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.9 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -19.79 | |||||
| ROA % | -19.08 | |||||
| ROIC % | -3003.62 | |||||
| ROC (Joel Greenblatt) % | -5170.44 | |||||
| ROCE % | -25 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.95 | |||||
| Price-to-Tangible-Book | 0.95 | |||||
| EV-to-EBIT | -43.07 | |||||
| EV-to-EBITDA | -43.46 | |||||
| EV-to-FCF | -57.1 | |||||
| Price-to-Net-Current-Asset-Value | 0.95 | |||||
| Price-to-Net-Cash | 0.96 | |||||
| Earnings Yield (Greenblatt) % | -2.32 | |||||
| FCF Yield % | -1.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ABIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ARCA biopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6 | ||
| Beta | 0 | ||
| Volatility % | 108.24 | ||
| 14-Day RSI | 34.32 | ||
| 14-Day ATR ($) | 4.919509 | ||
| 20-Day SMA ($) | 38.205 | ||
| 12-1 Month Momentum % | 45.64 | ||
| 52-Week Range ($) | 18.72 - 53.88 | ||
| Shares Outstanding (Mil) | 1.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ARCA biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ARCA biopharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ARCA biopharma Inc Frequently Asked Questions
What is ARCA biopharma Inc(ABIO)'s stock price today?
The current price of ABIO is $25.50. The 52 week high of ABIO is $53.88 and 52 week low is $18.72.
When is next earnings date of ARCA biopharma Inc(ABIO)?
The next earnings date of ARCA biopharma Inc(ABIO) is 2024-10-18 Est..
Does ARCA biopharma Inc(ABIO) pay dividends? If so, how much?
ARCA biopharma Inc(ABIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers